Using nanoparticles to deliver microRNA treatments for triple negative breast cancer
Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer
['FUNDING_R01'] · METHODIST HOSPITAL RESEARCH INSTITUTE · NIH-11045760
This study is testing a new way to treat triple negative breast cancer by using tiny particles to deliver a special molecule directly to the tumors, hoping to shrink them and help patients feel better while causing fewer side effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | METHODIST HOSPITAL RESEARCH INSTITUTE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11045760 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel treatment for triple negative breast cancer (TNBC), which currently lacks effective targeted therapies. The approach involves using nanoparticles to deliver microRNA-22 directly to TNBC tumors, aiming to inhibit a protein called elongation factor 2-kinase (EF2K) that drives tumor growth. By specifically targeting TNBC cells, this method seeks to minimize side effects on normal tissues. The research will explore the effectiveness of this targeted delivery system in reducing tumor size and improving patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have not responded to standard treatments.
Not a fit: Patients with other subtypes of breast cancer or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective treatment option for patients with triple negative breast cancer.
How similar studies have performed: Previous research has shown promise in using nanoparticle delivery systems for cancer therapies, indicating potential success for this novel approach.
Where this research is happening
HOUSTON, UNITED STATES
- METHODIST HOSPITAL RESEARCH INSTITUTE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, ZHIHUI — METHODIST HOSPITAL RESEARCH INSTITUTE
- Study coordinator: WANG, ZHIHUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy